



PATENT

Case Docket No. TRIPEP.005C1

Date: October 7, 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Anders Vahlne

) I hereby certify that this correspondence and all
marked attachments are being deposited with the
United States Postal Service as first class mail in
an envelope addressed to: United States Patent
and Trademark Office, P.O. Box 2327,
Arlington, VA 22202, on

Appl. No. : 10/072,783

)) October 7, 2002

Filed : February 8, 2002

)) (Date)

For : PROTEIN POLYMERIZATION
INHIBITORS AND METHODS
OF USE

)) Eric S. Furman, Ph.D., Reg. No. 45,664

Examiner : Chih Min Kam

))

Group Art Unit : 1653

))

TRANSMITTAL LETTER

United States Patent and Trademark Office
P.O. Box 2327
Arlington, VA 22202

Dear Sir:

Enclosed for filing in the above-identified application are:

- (X) An Information Disclosure Statement.
- (X) A PTO Form 1449 with seventy-eight (78) references.
- (X) The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.
- (X) Return prepaid postcard.

Eric S. Furman, Ph.D.
Registration No. 45,664
Attorney of Record



PATENT

TECH CENTER 1600
SAC 112
10/16/02

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Anders Vahlne) Group Art Unit 1653
App. No. : 10/072,783)
Filed : February 8, 2002)
For : PROTEIN POLYMERIZATION INHIBITORS)
AND METHODS OF USE)
Examiner : Chih Min Kam)

INFORMATION DISCLOSURE STATEMENT

United States Patent and Trademark Office
P.O. Box 2327
Arlington, VA 22202

Dear Sir:

Enclosed is form PTO-1449 listing references that are also enclosed. A copy of the Bachem Catalog, cited on form PTO-1449 as **reference number 79 is not enclosed**. This catalog was cited by the Examiner in U.S. Application No. 09/370,368, now U.S. Patent No. 6,258,932, however, applicant has been unable to obtain a copy for submission. This Information Disclosure Statement is being filed before the receipt of a first Office Action on the merits, and presumably no fee is required in accordance with 37 C.F.R. § 1.97(b)(3). If a first Office Action on the merits was mailed before the mailing date of this Statement, the Commissioner is authorized to charge the fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: 10/17/02

By: ESF
Eric S. Furman, Ph.D.
Registration No. 45,664
Attorney of Record
Customer No. 20,995

FORM PTO-1449

U. S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY DOCKET NO
TRIPEP.005C1APPLICATION NO
10/072,783

OCT 16 2002

INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT
Anders VahlneFILING DATE
February 8, 2002GROUP
1653

SEARCH CENTER 1653 2002

RECEIVED

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
1	6,455,670	09/24/02	van der Spoel et al.			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
2	WO 90/04390	05/01/90	WIPO				
3	0 421 074 A1	04/01/91	Europe				
4	2 668 488 A1	04/30/92	France				
5	WO 92/20795	11/01/92	WIPO				
6	WO 96/27386	09/01/96	WIPO				
7	WO 96/28162	09/19/96	WIPO				
8	WO 96/35714	11/01/96	WIPO				
9	WO 98/09985	03/01/98	WIPO				
10	WO 98/35062	08/01/98	WIPO				
11	0 894 855 A2	02/03/99	Europe				
12	WO 99/09056	02/25/99	WIPO				
13	WO 99/09985	03/04/99	WIPO				
14	0 900 566 A1	03/10/99	Europe				
15	WO 00/09158	02/01/00	WIPO				
16	WO 01/10456	02/15/01	WIPO				
17	WO 01/10457	02/15/01	WIPO				

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
18	Abdel-Meguid et al., "An orally bioavailable HIV-1 protease inhibitor containing an imidazole-derived peptide bond replacement: Crystallographic and pharmacokinetic analysis," <i>Biochemistry</i> , 33(39):11671-11677 (1994).
19	Allured et al., "Structure of exotoxin A of <i>pseudomonas aeruginosa</i> at 3.0- angstrom resolution," <i>Proc Natl Acad Sci USA</i> , 83(5):1320-1324 (1986).
20	Armstrong et al., "A phase 1 study of chemically synthesized verotoxin (Shiga-like toxin) Pk-trisaccharide receptors attached to chromosorb for preventing hemolytic-uremic syndrome," <i>J. Infectious Diseases</i> , J14 171:1042-1045 (1995)
21	Armstrong and Peppler, "Maintenance of biological activity of pertussis toxin radioiodinated while bound to fetuin," <i>Journal of Clinical Endocrinology</i> , 129:1294-1299 (1987)

CITATION CONSIDERED

*EXAMINER: INITIAL IF CITATION CONSIDERED. WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609. DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT

P E FORM PTO-1449


U. S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY DOCKET NO
TRIPEP.005C1APPLICATION NO
10/072,7831 6 2002 INFORMATION DISCLOSURE STATEMENT
BY APPLICANT
(USE SEVERAL SHEETS IF NECESSARY)APPLICANT
Anders VahlneFILING DATE
February 8, 2002GROUP
1653TECH CENTER 1650
OCT 1 2002

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
22	Ashkenazi et al., "Safety and antitumor activity of recombinant soluble Apo2 ligand," <i>J Clinical Investigation</i> , 104(2):155-162 (1999).
23	Bai et al., "Characterization of the interaction of cryptophycin 1 with tubulin: binding in the vinca domain, competitive inhibition of dolastatin 10 binding, and an unusual aggregation reaction," <i>Cancer Research</i> , 56:4398-4406 (1996).
24	Barger et al., "Tumor necrosis factors α and β protect neurons against amyloid β -peptide toxicity: Evidence for involvement of a κ B-binding factor and attenuation of peroxide and Ca^{2+} accumulation," <i>Proc Natl Acad Sci USA</i> , 92:9328-9332 (1995).
25	Brandhuber et al., "Mapping the enzymatic active site of pseudomonas aeruginosa exotoxin A," <i>Proteins</i> , 3(3):146-154 (1988).
26	Choe et al., "The crystal structure of diphtheria toxin," <i>Nature</i> , 357(6375):216-222 (1992).
27	Chothia and Janin, "Principles of protein-protein recognition," <i>Nature</i> , 256(5520):705-708 (1975).
28	Conner et al., "Selective Proteasome Inhibition Attenuates Experimental Polyarthritis Via Inhibition of Nuclear Transcription Factor κ B (NF- κ B) Activation," <i>Arthritis and Rheumatism, Abst. Suppl.</i> , 40(9), (1997).
29	Conner et al., "Proteasome Inhibition Attenuates Nitric Oxide Synthase Expression, VCAM-1 Transcription and the Development of Chronic Colitis," <i>Journal of Pharmacology and Exp Therapeutics</i> , 282(3):1615-1622, 1997.
30	Durso et al., "The antimitotic tripeptide hemiasterlin," <i>Proc Am Assoc Cancer Res Annual Meeting</i> , Vol. 40, p. 286, March 1999.
31	Erickson et al., "Design, activity, and 2.8 A crystal structure of a C2 symmetric inhibitor complexed to HIV-1 protease," <i>Science</i> , 249(4968):527-533 (1990).
32	Gamble et al., "Structure of the carboxyl-terminal dimerization domain of the HIV-1 capsid protein," <i>Science</i> , 278:849-853 (1997).
33	Glenner et al., "Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein," <i>Biochem Biophys Res Commun</i> , 120(3):885-890 (1984).
34	Grannelli-Piperno, et al., "Efficient Interaction of HIV-1 with Purified Dendritic Cells via multiple chemokine Coreceptors," <i>J Exp Med</i> , 184:2433-2438 (1996).
35	Hall et al., "Substituted 4-hydroxyproline di- and tri-peptides as cytotoxic agents," <i>Amino Acids</i> , 16(1):79-89 (1999).
36	Head et al., "Preparation of VT1 and VT2 hybrid toxins from their purified dissociated subunits," <i>J Biol Chem</i> , 266(6):3617-3621 (1991).
37	Henderson et al., "Gag proteins of the highly replicative MN strain of human immunodeficiency virus type 1: posttranslational modifications, proteolytic processing, and complete amino acid sequences," <i>Journal of Virology</i> , 66(4):1856-1865 (1992).
38	Hewlett et al., "Induction of a novel morphological response in Chinese hamster ovary cells by pertussis toxin," <i>Infect. Immun.</i> , 40(3):1198-1203 (1983).
39	Hilbich et al., "Substitutions of hydrophobic amino acids reduce the amyloidogenicity of alzheimer's disease β A4 peptides," <i>J Mol Biol</i> , 228:460-473 (1992).
40	Huang et al., "The role of DNA in the mechanism of NF- κ B dimer formation: crystal structures of the dimerization domains of the p50 and p65 subunits," <i>Structure</i> , 5(11):1427-1436 (1997).
41	Hwang et al., "Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1," <i>Science</i> , 253:71-74 (1991).
42	Ito et al., "Isolation and some properties of A and B subunits of Vero toxin 2 and in vitro formation of hybrid toxins between subunits of Vero toxin 1 and Vero toxin 2 from Escherichia coli O157:H7," <i>Microb Pathog</i> , 5(3):189-195 (1988).
43	Jarret and Lansbury, "Seeding 'One-dimensional crystallization' of amyloid: a pathogenic mechanism in alzheimer's disease and scrapie?" <i>Cell</i> , 73:1055-1058 (1993).
44	Kowalski et al., "Functional regions of the envelope glycoprotein of human immunodeficiency virus type I," <i>Science</i> , 237:1351-1355 (1987).

EXAMINER

*EXAMINER: INITIAL IF CITATION CONSIDERED. WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 600. DRAW LINE THROUGH CITATION IF NOT
IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT

RECEIVED



U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)	ATTY DOCKET NO. TRIPEP.005C1	APPLICATION NO 10/072,783
	APPLICANT Anders Vahlne	
	FILING DATE February 8, 2002	GROUP 1653


TECH CENTER 1653

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
45	Lassila et al., "A Role for Lys-His-Gly-NH ₂ in Avian and Murine B Cell Development," <i>Cell. Immun.</i> , 122:319-328, (1989).
46	Latimer et al., "The N-terminal domain of IκB α Masks the nuclear localization signal(s) of p50 and c-Rel homodimers," <i>Mol. Cell Biol.</i> , 18(5):2640 (1998).
47	LeVine, "Thioflavine T interaction with synthetic Alzheimer's disease beta-amyloid peptides: detection of amyloid aggregation in solution," <i>Protein Science</i> , 2(3):404-410 (1993).
48	Lingwood, "Role of verotoxin receptors in pathogenesis," <i>Trends in Microbiology</i> , 4(4):147-153 (1996).
49	Lobet et al., "Site-specific alterations in the B oligomer that affect receptor-binding activities and mitogenicity of pertussis toxin," <i>J Exp Med</i> , 177(1):79-87 (1993).
50	Loosmore et al., "Characterization of pertussis toxin analogs containing mutations in B-oligomer subunits," <i>Infect Immun</i> , 61(6):2316-2324 (1993).
51	Louis et al., "Hydrophilic peptides derived from the transframe region of GaPol inhibit the HIV-1 protease," <i>Biochemistry</i> , 37(8):2105-2110 (1998).
52	Maldonado et al., "Experimental chemotherapy with combinations of ergosterol biosynthesis inhibitors in murine models of chagas' disease," <i>Antimicrobial Agents and Chemotherapy</i> , 37(6):1353-1359 (1993).
53	Malek et al., "IκB α Functions through direct contacts with the nuclear localization signals and the DNA binding sequences of NF- α B," <i>J. Biol. Chem.</i> , 273(39):25427-25435 (1998).
54	Martin, "Fast-acting slow viruses," <i>Nature</i> , 345:572-573 (1990).
55	Masters et al., "Amyloid plaque core protein in Alzheimer disease and Down syndrome," <i>Proc Natl Acad Sci USA</i> , 82(12):4245-4249 (1985).
56	Memar O. et al., "Antiviral Agents in Dermatology; Current Status and Future Prospects," <i>International Journal of Dermatology</i> , 34(9):597-606 (1995).
57	Merritt, et al., "Surprising leads for a cholera toxin receptor-binding antagonist: crystallographic studies of CTB mutants," <i>Structure</i> , 3(6):561-570 (1995).
58	Miller, et al., "Antiviral activity of carbobenzoxy Di- and Tripeptides on measles virus," <i>Applied Microbiology</i> , 16(10):1489-1496 (1968).
59	Monks et al., "feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines," <i>J. National Cancer Institute</i> , 83(11):757-766 (1991).
60	Mukaida, et al., "Novel insight into molecular mechanism of endotoxin shock: biochemical analysis of LPS receptor signaling in a cell-free system targeting NF- κ B and regulation of cytokine production/action through β 2 integrin in vivo," <i>Journal of Leukocyte Biology</i> , 59(2):145-151 (1996).
61	Niedrig et al., "Inhibition of infectious human immunodeficiency virus type 1 particle formation by Gag protein derived peptides," <i>Journal of General Virology</i> , 75:1469-1474 (1994).
62	Owollen et al., "Inhibition of tubulin-microtubule polymerization by drugs of the Vinca alkaloid class," <i>Cancer Res.</i> , 36(4):1499 (1976).
63	Palker et al., "Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides," <i>Proc. Natl. Acad. Sci. USA</i> , 85(6):1932-1936 (1988).
64	Prusiner, "Some speculations about prions, amyloid, and Alzheimer's disease," <i>N. Engl. J. Med.</i> , 310(10): 661-663 (1984).
65	Prusiner, "Molecular biology of prion diseases," <i>Science</i> , 252(5012):1515-1522 (1991).
66	Rao et al., "3'-(p-azidobenzamido)taxol photolabels the N-terminal 31 amino acids of beta-tubulin," <i>J. Biol. Chem.</i> , 269(5):3132-3134 (1994).
67	Richards, "Inhibition of the aspartic proteinase from HIV-2," <i>FEBS Letters</i> , 253(1,2):214-216 (1989).
68	Sawada et al., "Identification of the fragment photoaffinity-labeled with azidodansyl-rhizoxin as Met-363-Lys0379 on beta-tubulin," <i>Biochem. Pharmacol.</i> , 45(7):1387-1394 (1993).
69	Sheha et al. "Synthesis of di- and tripeptide analogues containing α -ketoamide as a new core structure for inhibition of HIV-1 protease," <i>Eur. J. Med.</i> , 35(10):887-894 (2000).

DATE CONSIDERED:

*EXAMINER: INITIAL IF CITATION CONSIDERED. WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609. DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT

RECEIVED



U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)	ATTY. DOCKET NO TRIPEP.005C1	APPLICATION NO 10/072,783
	APPLICANT Anders Vahlne	
	FILING DATE February 8, 2002	GROUP 1653
	TECH. CENTER 1600 OCT 15 2002	

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
70	Sigma, Peptide and Amino Acid Catalog , p. 27 and p. 70, Copyright 1995-96.
71	Sixma et al., "Comparison of the B-pentamers of heat-labile enterotoxin and verotoxin-1: two structures with remarkable similarity and dissimilarity," <i>Biochemistry</i> , 32(1):191-198 (1993).
72	Sixma et al., "Refined structure of Escherichia coli heat-labile enterotoxin, a close relative of cholera toxin," <i>J. Mol. Biol.</i> , 230(3):890-918 (1993).
73	Stein et al., "Crystal structure of the cell-binding B oligomer of verotoxin-1 from E. coli," <i>Nature</i> , 355:748-750 (1992).
74	Su et al., "The nontoxic tripeptide glycyl-prolyl-glycine amide inhibits the replication of human immunodeficiency virus type 1," <i>Journal of Human Virology</i> , 4(1):1-7 (2001).
75	Su et al., "The tripeptide glycyl-prolyl-glycine amide does not affect the early steps of the human immunodeficiency virus type 1 replication," <i>Journal of Human Virology</i> , 4(1):8-15 (2001).
76	Van Der Spoel et al., "Tripeptide Amides that Block Viral Infectivity and Methods of use Thereof," U.S. Patent Application Serial No. 09/938,806, filed August 24, 2001.
77	Van Der Spoel et al., "Pentamer Peptide Amide, ALGPGNH2, which Inhibits Viral Infectivity and Methods of Use Thereof," U.S. Patent Application Serial No. 10/217,933, filed August 12, 2002.
78	Goobar-Larsson et al., "Molecules that Block Viral Infectivity and Methods of Use Thereof," U.S. Patent Application Serial No. 10/217,933, filed September 3, 2002.
79	Bachem Catalog , Bachem Bioscience Inc. 1993, pages 28, 29, 34, 145, 267, 332, 333, 457, 535, 536, 541, 546 and 553.

S:\DOCS\DAI\DAI-1715.DOC
091002

111 CONSIDERED

*EXAMINER: INITIAL IF CITATION CONSIDERED. WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609. DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT